Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
ATI-450 is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2 clinical development.
- ATI-450 is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2 clinical development.
- This mechanism leads to the inhibition of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals.
- Key inflammatory cytokines driven by this mechanism include tumor necrosis factor (TNF) and interleukin-1, -1, -6 and -8 (IL1, IL1, IL6 and IL8).
- These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.